# James L. Gulley

Source: https://onco.cc/people/james-gulley/  
OnCo record `james-gulley` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Runs NCI's immuno-oncology clinical programme, from prostate cancer vaccines to bifunctional checkpoint fusion proteins.

## Summary

James L. Gulley is Co-Director of the Center for Immuno-Oncology in the Center for Cancer Research at the National Cancer Institute. He is a medical oncologist who runs NCI's immuno-oncology clinical programme, from prostate cancer vaccines to bifunctional checkpoint fusion proteins, having led the PROSTVAC programme and early studies of bintrafusp alfa. His selected paper reports the phase 3 trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. He coordinates immuno-oncology trials across NCI's intramural programme in prostate, bladder and other genitourinary cancers.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Co-Director, Center for Immuno-Oncology, Center for Cancer Research
- Specialisms: Genitourinary cancers; Cancer vaccines; Bifunctional immunotherapies

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/James_L._Gulley
- NCI CCR profile: https://ccr.cancer.gov/staff-directory/james-l-gulley
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Gulley%20JL%5BAuthor%5D

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Off-the-shelf cancer vaccines](https://onco.cc/technologies/shared-antigen-vaccine/)
- institutions: [National Cancer Institute (NIH)](https://onco.cc/institutions/nci/), [NCI Center for Cancer Research (intramural programme)](https://onco.cc/institutions/nci-ccr/)

---
JSON: https://onco.cc/api/v1/entities/james-gulley.json